NAARDEN, the Netherlands and MIAMI, March 25, 2024 NewAmsterdam Pharma Company N.V. , a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk.
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
1. 92.4% of children in high-income countries had heterozygous familial hypercholesterolemia compared to 48.0% in non-high-income countries. 2. The majority of patients with confirmed heterozygous familial hypercholesterolemia were not on any lipid-lowering medication. Evidence Rating Level: 2 (Good) Study Rundown: Familial hypercholesterolemia affects more than 450,000 children worldwide each year, yet only a small proportion
Verve Therapeutics: Revolutionizing Cardiovascular Health (NASDAQ:VERV) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.